You are here: All Products  > EpimAb Out-licenses Use of its Bispecific Platform to Almirall in $210 Million Agreement

EpimAb Out-licenses Use of its Bispecific Platform to Almirall in $210 Million Agreement

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products